John Francis Crowley
Founder of Amicus Therapeutics, Inc., Orexigen Therapeutics, Inc. and Novazyme Pharmaceuticals, Inc., John Francis Crowley is an entrepreneur and businessperson who has been at the helm of 5 different companies and occupies the position of Chairman & Chief Executive Officer for Amicus Therapeutics, Inc. and President at Scioderm, Inc. (a subsidiary of Amicus Therapeutics, Inc.). Mr. Crowley is also Member of The Wall Street Journal CEO Council and on the board of 5 other companies.
Mr. Crowley previously occupied the position of Director-Business Strategy at Bristol Myers Squibb Co., President & Chief Executive Officer for Orexigen Therapeutics, Inc., President & Chief Executive Officer for Novazyme Pharmaceuticals, Inc., Litigation Associate-Health Care Practice Group at Bingham Summers Welsh & Spilman, Senior Vice President of Genzyme Therapeutics Ltd. and National Chairman at Make-A-Wish Foundation of America.
He received an undergraduate degree from Georgetown University, a graduate degree from the University of Notre Dame The Law School and an MBA from Harvard Business School.
|10/11/2021||2,500||Disposition at $119.55 per share.||298,875|
|10/11/2021||2,500||Derivative/Non-derivative trans. at $18.83 per share.||47,075|
|10/05/2021||200||Disposition at $132.84 per share.||26,568|
|10/05/2021||1,846||Disposition at $131.74 per share.||243,193|
|10/05/2021||3,759||Disposition at $130.92 per share.||492,129|
|10/05/2021||2,915||Disposition at $129.88 per share.||378,601|
|10/05/2021||1,280||Disposition at $128.83 per share.||164,903|
|10/05/2021||10,000||Derivative/Non-derivative trans. at $18.83 per share.||188,300|